What is the core of the Galenica Bichsel closure plan?

Galenica will stop Bichsel’s drug production by end 2026, affecting up to 170 roles in Switzerland. The company expects CHF35–40 million in one-off costs, mostly in H1, and will shift resources toward home care services. Management targets about CHF3 million in annual EBIT uplift starting in 2027.

How did GALE.SW react to the news today?

Shares traded at CHF95.40, down 6.3%, with volume roughly double the average. The price touched CHF93.50 intraday and met resistance near CHF98. Technicals lean cautious, with RSI near 36 and price near the lower Bollinger band, signaling short-term pressure after the Galenica Bichsel closure update.

Why is Galenica pivoting to home care?

Home care can deliver steadier demand and better margins than manufacturing. In Switzerland, aging demographics and chronic conditions support in-home services. The Galenica Bichsel closure reduces complexity and capital needs, aiming to improve the earnings mix and deliver a modest CHF3 million EBIT uplift from 2027.

What should investors watch before the next results?

Focus on the timing of one-off costs in H1, clarity on the Bichsel wind-down, and early signs of service revenue growth. Watch cash conversion, leverage near 2.34x net debt to EBITDA, and management’s confirmation of the CHF3 million EBIT uplift from 2027 during the March 10 results update.

Global Market Insights

GALE.SW Stock Today: Bichsel Exit, CHF40m Charge — February 25

ByHuzaifa Zahoor February 25, 2026February 25, 2026

Galenica Bichsel closure dominates Swiss market talk today as GALE.SW trades at CHF95.40, down 6.3%. Management will wind down Bichsel’s drug production by end 2026, record CHF35–40 million in one-off costs, and pivot to higher-margin home care. The plan implies near-term earnings noise but a cleaner mix ahead. From 2027, Galenica targets about CHF3 million annual EBIT uplift. Investors in Switzerland should weigh short-term pressure against longer-term service growth and capital discipline.